1 Guidance

1 Guidance

1.1 Current evidence on the efficacy of epiretinal brachytherapy for wet age-related macular degeneration (AMD) is inadequate and limited to small numbers of patients. With regard to safety, vitrectomy has well-recognised complications and there is a possibility of subsequent radiation retinopathy. Therefore this procedure should only be used in the context of research. Research studies should address whether epiretinal brachytherapy reduces the progression of wet AMD and whether it can reduce the number of injections of antivascular endothelial growth factor agents (anti-VEGF) required. Long-term outcomes should be reported.

  • National Institute for Health and Care Excellence (NICE)